# üß™ TEST CASES - 10 REAL-WORLD SCENARIOS

**Philosophy**: Test before building - see what works, what breaks

---

## **Category 1: Food & Supplements** (Tests 1-4)

### Test 1: Vitamin D ‚Üí Ovarian Cancer ‚úÖ
- **Expected**: WORKS (existing capability)
- **Targets**: VDR
- **Pathways**: TP53 (0.955), inflammation
- **Output**: CONSIDER (moderate alignment)

### Test 2: Curcumin ‚Üí Breast Cancer ‚ö†Ô∏è
- **Expected**: May fail (disease not in OLD system)
- **Targets**: NFŒ∫B, COX2
- **Pathways**: PIK3CA (0.827), inflammation

### Test 3: Resveratrol ‚Üí Pancreatic Cancer ‚ö†Ô∏è
- **Expected**: May fail (pathways missing)
- **Targets**: SIRT1, multiple
- **Pathways**: KRAS (0.854)

### Test 4: Omega-3 ‚Üí Alzheimer's ‚ùå
- **Expected**: Will fail (non-cancer)
- **Targets**: Neuroinflammation
- **Pathways**: Not in database

---

## **Category 2: Drug Repurposing** (Tests 5-6)

### Test 5: Metformin ‚Üí Glioblastoma ‚ö†Ô∏è
- **Expected**: May fail (disease missing)
- **Targets**: AMPK, mTOR
- **Mechanism**: Activation (not inhibition)

### Test 6: Aspirin ‚Üí Colorectal Cancer ‚ö†Ô∏è
- **Expected**: May fail (prevention vs treatment)
- **Targets**: COX1/COX2
- **Context**: Prevention hypothesis

---

## **Category 3: Therapeutic Design** (Tests 7-8)

### Test 7: Anti-VEGF Nanobody ‚Üí Ovarian ‚ùå
- **Expected**: Will fail (endpoint doesn't exist)
- **Phase**: Requires Phase 2 (Forge)

### Test 8: IL-6 Inhibitor ‚Üí Multiple Myeloma ‚ùå
- **Expected**: Will fail (endpoint doesn't exist)
- **Phase**: Requires Phase 2 (Forge)

---

## **Category 4: CRISPR Design** (Tests 9-10)

### Test 9: KRAS G12D gRNA ‚Üí Pancreatic ‚ö†Ô∏è
- **Expected**: May partially work (Design Router exists)
- **Missing**: Boltz validation

### Test 10: TP53 R175H Base Edit ‚Üí Ovarian ‚ùå
- **Expected**: Will fail (base editing not implemented)

---

**Test Scripts**: See `AGENT_JR_TESTING_HANDOFF.mdc`
**Results**: Document in `TEST_WAVE_1_COMPLETE_RESULTS.md`
